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Sterol regulatory element-binding proteins (SREBPs) are transcriptional factors that control lipid and 
cholesterol metabolism. Activation of SREBPs in response to a decrease in the cellular sterols results in 
acceleration of the synthesis of fatty acids, triglycerides, and cholesterol. Aberrant SREBP activity has 
been linked to metabolic disease states, such as obesity, fatty liver, insulin resistance, hyperlipidemia, and 
atherosclerosis. Thus, inhibition of SREBP activation is a potential therapeutic approach to treating 10 
metabolic disorders. This review focuses on direct or indirect small-molecule inhibitors of SREBP 
activation. 
Introduction 
Sterol regulatory element-binding proteins (SREBPs) are one of 
the most important families of transcription factors involved in 15 
lipid homeostasis. SREBPs control cellular metabolism in all 
tissues by regulating the expression of the genes related to 
biosynthesis and uptake of fatty acids, triglycerides, cholesterol, 
and phospholipids.1,2 The central roles of SREBPs in lipid 
metabolism link them tightly to metabolic syndromes. For 20 
example, high insulin levels, induced by high calorie diets or 
obesity, hyper-activate SREBPs, causing triglyceride 
accumulation and inducing fatty liver diseases.3,4 Hyper-
activation of SREBPs also increases cholesterol levels and 
suppresses insulin receptor substrate (IRS)-2, leading to 25 
hyperlipidemia, arteriosclerosis, and insulin resistance.5,6 
Furthermore, activation of SREBPs is often correlated with the 
growth of cancers and the ability of hepatitis virus to cause fatty 
liver diseases.7,8 The involvement of SREBP activation in the 
multiple diseases has made these transcription factors attractive 30 
pharmaceutical targets.9 This review summarizes recent studies of 
small molecules that directly or indirectly suppress the cellular 
functions of SREBPs. 
Regulation of SREBP pathway 
The SREBP family 35 
In mammals, the SREBP family consists of three isoforms, 
SREBP-1a, -1c, and -2, which play overlapping, but distinct, 
roles.1 SREBP-1a, which usually exists in proliferating cells, 
promotes the synthesis of fatty acids and cholesterol. In contrast, 
SREBP-1c is expressed mainly in the liver, and primarily 40 
stimulates fatty acid and triglyceride synthesis by inducing 
transcription of the genes necessary to convert acetyl CoA into 
fatty acids and triglycerides, e.g., fatty acid synthase (FAS), 
stearoyl-CoA desaturase 1 (SCD-1), and acetyl-CoA carboxylase 
(ACC).10 SREBP-2 is also expressed in the liver, and primarily 45 
activates genes involved in cholesterol synthesis and uptake, 
including 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), 
and low-density lipoprotein receptor (LDLR).2 
The synthesis of SREBP 
SREBPs are basic helix-loop-helix leucine zipper (bHLH-LZ) 50 
transcription factors. SREBP-1a and -1c are encoded by a single 
gene and generated by an alternative splicing of exon 1.11 The 
expression of SREBP-1c gene is self-controlled, and is stimulated 
by both insulin and oxysterols through activation of the nuclear 
hormone receptor, liver X receptor (LXR).12-14 When stimulated 55 
by insulin, LXR heterodimerizes with retinoid X receptor (RXR). 
The heterodimer interacts with LXR-responsive elements located 
in the SREBP-1c promoter, stimulating transcription of the 
SREBP-1c gene.13 SREBP-2 is encoded by another gene, whose 
splicing variants have not been discovered.11 60 
The proteolytic activation of SREBP  
Unlike other transcription factors in the bHLH-LZ family, 
SREBPs are newly synthesized on the endoplasmic reticulum 
(ER) membrane as inactive precursors (Fig. 1).14 On the ER, The 
C-terminal domain of SREBPs binds to SREBP cleavage-65 
activating protein (SCAP). The SREBP-SCAP complex is 
transported from the ER to the Golgi apparatus via COPII 
vesicles (Fig. 1A). In the Golgi apparatus, SREBPs are 
sequentially cleaved by two proteases: site-1 protease (S1P), a 
membrane-bound serine protease also known as SKI-1; and site-2 70 
protease (S2P), a Zn2+ metalloprotease, and the N-terminal 
domains of SREBPs, which are transcriptionally active fragments 
of SREBPs, are generated.  
 SCAP is an indispensable protein for SREBP activation, both 
in vitro and in vivo. In addition to acting as an escort protein for 75 
SREBPs, physical association with SCAP seems to stabilize 
SREBPs. In SCAP-deficient CHO cells, both the precursor and 
the nuclear form of SREBPs disappear.15 Without SCAP, 
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Fig. 1 The pathway of SREBP activation. 
 
Fig. 2 Chemical structures of cholesterol and oxysterols. 
SREBPs in the ER are unstable and cannot translocate to the 5 
Golgi apparatus. In hepatic SCAP-deficient mice, basal rates of 
cholesterol and fatty acid synthesis in the liver were reduced by 
80%, due to decreases in mRNAs that encode multiple 
biosynthetic enzymes.16 
 The proteolytic activation of SREBP is tightly regulated by a 10 
negative feedback loop with cholesterol, in which the ER-resident 
proteins, Insig-1 and Insig-2, play an important role.2,17 When 
cellular sterol levels are high, cholesterol (Fig. 2) binds to SCAP, 
and 25-hydroxycholesterol (Fig. 2), a metabolite of cholesterol, 
binds to the Insig proteins.18,19 The binding of cholesterol to 15 
SCAP, or of 25-hydroxycholesterol to Insig proteins, stimulates 
formation of an SREBP-SCAP-Insig complex (Fig. 1B). The 
binding of Insig protein to SCAP blocks the interaction of SCAP 
with COPII, so that the SREBP-SCAP complex is retained in the 
ER.20 Thus, excess sterols inhibit translocation of the SREBP-20 
SCAP complex to the Golgi apparatus, and activation of SREBPs 
is blocked. 
 In addition to 25-hydroxycholesterol, other oxysterols that are 
generated under excess cholesterol conditions, such as 24(S)-
hydroxycholesterol and 27-hydroxycholesterol (Fig. 2), block the 25 
processing of SREBPs, especially SREBP-2, by the same 
mechanism as that of 25-hydroxycholesterol.19 
The regulation of the nuclear form of SREBP 
The cleaved SREBP N-terminal domains (the nuclear form of 
SREBP) are released from the membrane of the Golgi apparatus 30 
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 Fig. 3 Multiple regulation of SREBP activation by small molecules. 
motifs known as sterol regulatory elements (SREs) as dimers.11 
They promote the expression of all genes encoding the enzymes 
required to convert acetyl CoA into fatty acids and cholesterol 5 
(Fig. 1).2 
 The translocation and stability of the nuclear form of SREBP 
are controlled by a number of enzymes: a phosphatase, a kinase, 
and a deacetylase. Insulin, the major activator of SREBP-1c in 
the liver, promotes the activation of SREBP-1c via multiple 10 
pathways.21,22 One pathway is via the activation of Akt (also 
known as protein kinase B) and mammalian target of rapamycin 
(mTOR) kinase. Insulin activates phosphatidylinositol 3-kinase 
(PI3K) by inducing phosphorylation of IRS-1/2, promoting the 
conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to 15 
phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 binds to 
and activates Akt, which directly phosphorylates tuberous 
sclerosis complex 1/2 (TSC1/2) and PRAS40, leading to the 
activation of mTOR complex 1 (mTORC1). Activated mTORC1 
phosphorylates lipin-1, a phosphatidic acid phosphatase, and 20 
inhibits its translocation to the nucleus. Dephosphorylated, 
nuclear, catalytically active lipin-1 promotes nuclear remodeling 
and decreases the nuclear abundance of SREBP-1c.23 Therefore, 
mTORC1 activation would result in increased nuclear SREBP-1c 
(Fig. 3). In addition to the lipin-1-mediated regulation of SREBPs, 25 
mTORC1 activation has been reported to stimulate proteolytic 
SREBP-1c processing via activation of p70 S6-kinase (S6K), 
although the detailed mechanism remains unknown (Fig. 3).24  
 Another enzyme regulating the nuclear SREBP is adenosine 5'-
monophosphate-activated protein kinase (AMPK), an important 30 
enzyme that monitors cellular energy status.25 AMPK, activated 
in response to cellular metabolic stresses, phosphorylates and 
inactivates ACC and HMGCR, key enzymes involved in 
regulating de novo biosynthesis of fatty acids and cholesterol.26 
Interestingly, the latter two enzymes are encoded by the target 35 
genes of SREBPs, and the activation of AMPK and SREBP-1c in 
liver is inversely correlated.27 Recent studies showed that AMPK 
directly controls SREBPs: AMPK binds directly to and 
phosphorylates SREBP-1c or -2, blocking both the cleavage 
processing and the nuclear translocation of SREBPs (Fig. 3).28 40 
AMPK also inhibits PI3K/Akt/mTOR signaling, which as 
mentioned earlier, increases the amounts of nuclear SREBP-1c 
(Fig. 3).29 In addition, AMPK directly inhibits ligand-induced 
LXR activity on the SREBP-1c gene promoter (Fig. 3), although 
the detailed mechanism remains unknown.30  45 
 SIRT1 is an NAD+-dependent deacetylase involved in both 
glucose and lipid metabolism.31 Recent studies have shown that 
SREBPs are direct targets of SIRT1 (Fig. 3).32,33 SIRT1 increases 
the amounts of deacetylated SREBPs, which are susceptible to 
ubiquitin-mediated degradation, decreasing the nuclear SREBPs 50 
levels, and, consequently, the expression levels of SREBP-
responsive lipogenic genes. 
Inhibitors of the synthesis of SREBP 
LXR antagonists 
Nucleus
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Fig. 4 Chemical structures of LXR ligands. 
Diosgenin (Fig. 4), an aglycone of fenugreek that functions as an 
LXRα antagonist, down-regulates expression of SREBP-1c and 
its downstream genes, including FAS, ACC, and SCD-1, and 5 
suppresses triglyceride accumulation in HepG2 cells.34 
Administration of fenugreek to KK-Ay mice reduced the 
expression of hepatic SREBP-1c and decreased triglyceride levels 
in the blood and liver. Similarly, the synthetic LXR antagonists, 
GSK2033 and molecule 1 (Fig. 4), reduced the expression of 10 
SREBP-1c and triglyceride levels in cultured cells.35,36 GSK2033 
is a synthetic derivative of a hit molecule (2, Fig. 4) of a high-
throughput screening (HTS),35 and molecule 1 is an antagonist 
designed from the structure of the known LXR agonist, 
T0901317 (Fig. 4).36 15 
PUFAs 
Polyunsaturated fatty acids (PUFAs) in fish oil have long been 
known to inhibit synthesis of fatty acids and triglycerides, and to 
lower plasma triglyceride levels.37 In fact, eicosapentaenoate has 
been used clinically as a drug for hyperlipidemia. The lipid-20 
lowering effects of PUFAs are mediated, in part, by down-
regulation of the lipogenic function of SREBP-1c in the liver. 
 PUFAs suppress hepatic SREBP-1c transcriptionally (Fig. 3). 
Arachidonic acid, eicosapentaenoic acid, and docosahexaenoic 
acid (Fig. 5) down-regulate the expression of hepatic SREBP-1c 25 
by acting as antagonists of LXRα, thereby decreasing the 
expression levels of lipogenic enzymes.38-40 Oral administration 
of fish oil into animal models reduced the mRNA expression of 
SREBP-1c, as well as triglyceride levels in the liver.41 
 In addition to their effects on SREBP-1c, PUFAs are known to 30 
be ligands for peroxysome proliferator-activated receptor (PPAR) 
alpha,42,43 a nuclear receptor that controls lipid and glucose 
metabolism. PUFAs also inhibit the hepatic maturation of 
carbohydrate-responsive element-binding protein (ChREBP),44 a 
glucose-activated transcription factor involved in lipogenesis in 35 
the liver. Thus, inhibition of SREBP activation is probably only 
one of multiple mechanisms and targets by which PUFAs exert 









docosahexaenoic acid  
Fig. 5 Chemical structures of PUFAs. 40 
PPARα  agonists 
Recent investigation revealed that ligands of the PPAR family of 
nuclear receptors modulate SREBP activity (Fig. 3). Fibrates, 
anti-hyperlipidemia PPARα agonists, down-regulate triglyceride 
levels by promoting β-oxidation of fatty acids, and reduce very 45 
low-density lipoprotein (VLDL) levels by increasing adipose 
differentiation-related proteins.45  
 PPARα agonists appear to modulate the activity of SREBPs 
through LXR. Wy14,643 (Fig. 6) is a PPARα agonist that 
prevents LXR ligands from inducing SREBP-1c gene expression 50 
in primary rat hepatocytes and in mouse liver.46 The activation of 
PPARα somehow blocks the ability of the LXR/RXR 
heterodimer to stimulate promoter activity of SREBP-1c.  
 In contrast, results of another research on PPARα agonists 
reveal a discrepancy. A report claimed that Wy14,643 and 55 
GW7647 (another PPARα agonist, Fig. 6) enhanced activity of 
the SREBP-1c gene promoter through LXR elements, thereby 






































































Fig. 6 Chemical structures of PPARα agonists. 
hepatocytes.47 Inconsistent results might be due to differences in 
the species and nutritional status of cells used in the 
experiments.47 5 
FXR agonists 
Farnesoid X receptor (FXR) is a nuclear receptor whose 
endogenous agonist is bile acid, a steroid acid composed 
primarily of cholic acid derivatives that are biosynthesized via 
oxidation of cholesterol.48 The role of FXR in the metabolism of 10 
cholesterol, triglyceride, and glucose links it to SREBPs. 
Activation of FXR by FXR agonists (Fig. 7), such as cholic acid, 
chenodeoxycholic acid, or the synthetic agonist, GW4064, 
impairs the expression of SREBP-1c that is induced by high-fat 
diets or LXR ligands, ultimately decreasing the hepatic and renal 15 
levels of triglyceride.49,50 The decrease in SERBP-1c expression 
seems to be mediated by the binding of small heterodimer partner 
(SHP) to LXRα or other transcription factors that stimulate 
SREBP-1c expression (Fig. 3). This mechanism could account for 
the observation that administration of bile acid decreases hepatic 20 
secretion of VLDL.50 
Inhibitors of the proteolytic activation of SREBP 
Sterols inhibit SREBP activation. However, sterols themselves 
might not be suitable as selective pharmaceuticals for treating 
metabolic disorders, considering their effects on SREBP-1c along 25 
with their other physiological functions.51 Especially, oxysterols 
are endogenous ligands of LXRs,52-54 and stimulate the 
transcription of SREBP-1c via activation of LXRα in the liver 
(Fig. 3).55 By increasing SREBP-1c levels under sterol overload, 
the LXRs might ensure a sufficient supply of fatty acids to allow 30 
storage of excess cholesterol as cholesteryl ester.55 Thus, 
administration of oxysterols could decrease blood cholesterol 
level by suppressing SREBP-2 activation, and also induce 



























GW4064  35 
Fig. 7 Chemical structures of FXR agonists. 
There have been a number of investigations for discovering non-
sterol molecules that block the proteolytic activation of SREBP.   
Protease inhibitors 
S1P and S2P are essential for the proteolytic activation of 40 
SREBPs. Rates of fatty acid and cholesterol synthesis were 
reduced by 75% in the livers of mice with disrupted S1P gene.57 
The amounts of the nuclear form of SREBP and the expression 
levels of its target genes were also dramatically decreased. These 
observations suggested that S1P inhibitors could be effective as 45 
lipid-lowering drugs (Fig. 3). 
 S1P is inhibited by the general serine protease inhibitors, 3,4-
dichloroisocoumarin and 4-(2-aminoethyl)benzenesulfonyl 
fluoride (AEBSF) (Fig. 8).58,59 AEBSF also suppresses generation 
of the nuclear form of SREBP-2.58 However, these inhibitors are 50 
not selective for S1P. The peptide, decanoyl-Arg-Arg-Leu-Leu-
chloromethylketone (Dec-RRLL-CMK, Fig. 8), is an irreversible 
S1P inhibitor that is more selective than AEBSF for S1P,60 and 
impairs the maturation of SREBP-1/-2 in cultured cells.61 
 PF-429242 (Fig. 8), a non-peptidic, reversible, and highly 55 
selective inhibitor of S1P (IC50 = 0.17 µM) was discovered by a 
research group at Pfizer, Inc.62 This aminopyrrolidineamide 
derivative was derived from a hit molecule (3) of a HTS using 
purified human S1P. PF-429242 inhibits the processing of 
SREBP-2 and suppresses the expression of SREBP target genes 60 
in cultured cells.63 Hepatic rates of cholesterol and fatty acid 
synthesis were reduced in mice treated with PF-429242. 
 Inhibitors of S2P have also been reported. The metalloprotease 
inhibitor, 1,10-phenanthroline (Fig. 8), shows dose-dependent 
inhibitory effects on the protease activity of S2P.64 Nelfinavir  65 
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Fig. 8 Chemical structures of S1P and S2P inhibitors. 
(Fig. 8), a human immunodeficiency virus (HIV) protease 
inhibitor, inhibits S2P activity, and also down-regulates the 
processing of SREBP-1 and the expression of FAS in cultured 5 
cells.65,66 
 S1P and S2P are major enzymes controlling cholesterol and 
fatty acid synthesis, but are also involved in several homeostatic 
functions, such as the ER stress response, bone mineralization, 
and targeting of proteins to lysosomes.67 Dec-RRLL-CMK and 10 
nelfinavir exhibit cytotoxicity,65,68 possibly due to impaired 
processing of activating transcription factor 6 (ATF6), another 
substrate of S1P and S2P that is involved in the stress response.60, 
65 Thus, chronic use of S1P and S2P inhibitors might cause a 
range of side effects.67 15 
Inhibitors of SREBP-SCAP migration  
Two non-endogenous molecules that selectively inhibit SREBP 
activation have been discovered through chemical library 
screening.69,70 Both fatostatin and betulin (Fig. 9) inhibit 
migration of the SREBP-SCAP complex to the Golgi apparatus 20 
by directly binding to SCAP, and thereby down-regulate 
expression of the genes involved in cholesterol and fatty acid 
synthesis (Fig. 3). 
 Fatostatin was the first discovered non-endogenous molecule 
that inhibits SREBP-SCAP migration. Fatostatin, a synthetic 25 
small molecule with a non-steroidal structure, was originally 
described as an inhibitor of the insulin-stimulating differentiation 
of 3T3-L1 cells to adipocyte.71 Administration of fatostatin by 
intraperitoneal injection blocked increases in body weight, blood 
glucose, and hepatic fat accumulation in ob/ob mice, even under 30 
uncontrolled food intake.69 A structure-activity relationship study 
of fatostatin derivatives led to the discovery of FGH10019 (Fig. 
9), a potent inhibitor of SREBP activation with drug-like physical 
properties.72 Ob/ob mice fed normal chow containing FGH10019 
exhibited reduced body weight, serum cholesterol levels, and 35 



















Fig. 9 Chemical structures of inhibitors of SREBP-SCAP migration. 
 More recently, betulin, a pentacyclic triterpene which is a 
natural product abundant in birch bark, was identified to inhibit 40 
SREBP processing in a human hepatoma cell line.70 Mice fed a 
western-type diet, then treated with betulin through gastric 
irrigation, exhibited decreased lipid levels in serum and tissues, 
and increased insulin sensitivity. Administration of betulin to 
LDLR-knockout mice, an atherosclerosis disease model, reduced 45 
the size and improved the stability of atherosclerotic plaques. 
 The small molecules, including FGH10019 and betulin, that 
directly interact with the SREBP-SCAP complex and inhibit 
SREBP activation, improve lipid metabolism in vivo. 
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be an effective approach for treating hyperlipidemia and 
associated metabolic diseases. 
PUFAs 
PUFAs have been reported to suppress hepatic SREBP-1c post-
transcriptionally in addition to their effects on the SREBP 5 
synthesis. One possible mechanism by which PUFAs reduce lipid 
levels is inhibition of SREBP-1c maturation (Fig. 3). PUFAs, 
including eicosapentaenoic acid (Fig. 5), block the proteolytic 
processing of SREBP-1c and reduce amounts of the nuclear form 
of SREBP-1c, both in cells and in vivo.73-75 Inhibition of SREBP-10 
1c processing might be due to the loss of SCAP and/or S1P, 
which are required for proteolytic activation of SREBP-1c.76 
However, the mechanism by which eicosapentaenoic acid might 
induce the loss of SCAP and S1P remains unknown. On the other 
hand, arachidonic acid has been reported to inhibit the 15 
proteasomal degradation of Insig-1, potentiating the ability of 
sterols to block the proteolytic activation of SREBP-1c.77 
PPARα /γ  agonists 
As mentioned earlier, PPARα agonists modulate the synthesis of 
SREBP through LXR activity. Interestingly, activation of PPARα 20 
by Wy14,643 or clofibrate (another PPARα agonist, Fig. 6) also 
promotes the expression of Insig-1/2, thereby decreasing nuclear 
levels of SREBP-1 and -2, and impairing lipid synthesis in Fao 
cells and rat liver.78,79  
 Glitazones, PPARγ agonists used in the treatment of type 2 25 
diabetes mellitus, sensitize insulin response by promoting 
adipogenesis and glucose uptake.80 PPARγ agonists have also 
been reported to modulate the amount of the nuclear SREBPs 
(Fig. 3). Troglitazone (Fig. 10), a PPARγ agonist, reduces nuclear 
levels of SREBP-2 in HepG2 and Caco-2 cells, thus, decreasing 30 
the expression of SREBP-2-responsive genes, including HMGCR 
and LDLR, without increasing the expression levels of Insig-2.81 
On the other hand, troglitazone promotes the expression of Insig-
1/-2a in Fao cells, reducing the nuclear abundance of SREBP-1c 
and leading to a reduction in triglyceride synthesis.79 Pioglitazone 35 
(Fig. 10), another PPARγ agonist, completely repressed nuclear 
translocation of SREBP-1c in the liver of wild-type mice fed the 
methionine and choline-deficient (MCD) diet, preventing MCD-
induced steatohepatitis by an unknown mechanism.82 















Fig. 10 Chemical structures of PPAR γ agonists. 
discrepancies as with the effects on the synthesis of SREBP. Two 
studies reported that administration of clofibrate, fenofibrate 
(another PPARα agonist, Fig. 6), or troglitazone did not affect 45 
either the amount of nuclear SREBPs in mouse liver or the 
expression of SREBPs, Insigs, and SREBP target genes in the 
liver and adipose tissue of pigs.73,83 Another study reported that 
wild-type mice treated with Wy14,643 actually exhibited 
increased amounts of nuclear SREBP-1c and fatty acid synthesis 50 
in the liver.84 Inconsistent results of the effects on the amount of 
the nuclear SREBP would also be due to differences in the 
species and nutritional status of cells and animals used in the 
experiments.47,79 Thus, experimental effects of PPAR agonists on 
SREBPs should be interpreted with particular care. 55 
Inhibitors of the nuclear form of SREBP 
mTORC1 inhibitors 
The nuclear translocation of SREBP is controlled by mTORC1 
signaling pathway. Pharmacological inhibition of mTORC1 
might impair the nuclear translocation of SREBP (Fig. 3). The 60 
best known inhibitor of mTORC1 is rapamycin (Fig. 11). 
Rapamycin binds to FKBP12, and the resulting complex binds to 
and inactivates mTORC1.85 Treatment of hepatocytes and several 
other cell systems with this natural product impairs the insulin-
induced accumulation of nuclear SREBP-1, decreasing the 65 
expression levels of SREBP-responsive genes, including FAS and 
SCD-1.86,87 Similarly, in vivo administration of rapamycin blocks 
the diet-induced increase of hepatic SREBP-1c.87 Another known 
mTOR inhibitor is Torin1 (Fig. 11), a synthetic kinase inhibitor 
that binds to the ATP-binding pocket of mTOR (IC50 = 2 nM for 70 
mTORC1 in cells).88,89 This selective mTOR inhibitor also 






















Fig. 11 Chemical structures of mTORC1 inhibitors. 
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Fig. 12 Chemical structures of AMPK and SIRT1 activators. 
cells, which rapamycin fails to do.23 
AMPK activators 
Metformin (Fig. 12), an oral anti-diabetic drug in the biguanide 5 
class, activates AMPK.90 Metformin requires the kinase, LKB1, 
which phosphorylates and activates AMPK in the liver, and 
lowers blood glucose levels.91 Activation of AMPK mediates a 
reduction in expression of the hepatic gluconeogenic 
genes, PEPCK and Glc-6-Pase.92 Metformin and other well 10 
known AMPK activators (Fig. 12), including 5-aminoimidazole-
4-carboxamide-1-β-D-ribofuranoside (AICAR), natural 
polyphenol resveratrol, and the synthetic polyphenol, S17834, 
inhibit the activation of SREBP-1c and -2 in cells and in vivo, 
leading to the improvement of alcohol-induced fatty liver disease 15 
in rats or diet-induced fatty liver diseases in diabetic mouse 
models.28,90,93,94 The recently described AMPK activators, 
sauchinone and glabridin (Fig. 12), which are bioactive 
constituents of natural medicines, also suppress the expression 
levels of SREBP-1c and decrease triglyceride levels in liver and 20 
white adipose tissue of high fat diet-induced obese mice.95,96 
 These observations collectively suggest the exciting possibility 
that small-molecule AMPK activators might provide a 
pharmacological means of suppressing SREBPs, thereby 
impairing biosynthesis of fatty acids and cholesterols. A number 25 
of other AMPK activators have been discovered;97 however, their 
effects on SREBPs have not yet been investigated. Further 
research might lead to the discovery of clinically useful AMPK 
activators. 
SIRT1 activators 30 
Small molecules that activate SIRT1, resveratrol and SRT1720 
(Fig. 12), inhibit SREBPs in cells and in vivo, thereby decreasing 
levels of hepatic lipids and cholesterol, and improving alcoholic 
or non-alcoholic liver steatosis in mice.32,33,98 As discussed above, 
resveratrol also activates AMPK, so that administration of 35 
resveratrol activates both SIRT1 and AMPK in mouse liver.98 
Due to the crosstalk of SIRT1 and AMPK, it is unclear which 
factor is located upstream.99 Furthermore, although SRT1720 was 
originally discovered as an activator of SIRT1,100 its exact 
mechanism of action remains under debate.101 Better 40 
understanding of the mechanisms by which resveratrol and 
SRT1720 activate SIRT1 and AMPK is required for the 
development of more effective drug-like activators. Nevertheless, 
it seems clear that small-molecule activators of AMPK and 
SIRT1 might serve as SREBP modulators. 45 
Drugs with unknown mechanisms 
A number of molecules have apparent indirect effects on SREBP 
expression through unknown mechanisms. For example, 
bortezomib (Fig. 13), a proteasome inhibitor used to treat 
multiple myeloma, suppresses the mRNA expression of SREBP-50 
1c, thereby suppressing expression of downstream lipogenic 
genes and ultimately inhibiting alcohol-induced fatty liver.102 The 
detailed molecular mechanism of this surprising effect remains 
unclear; however, decreased expression of C/EBPα, a 
transcription factor upstream of SREBP, might partly be 55 
responsible for decreasing SREBP expression levels. On the other 
hand, pharmacological inhibition of proteasome has been 
reported to stabilize SREBPs, which are susceptible to ubiquitin-
proteasome degradation,103 and to increase expression levels of 
SREBP-responsive genes.103,104 The practical use of proteasome 60 
inhibitors for selective inhibition of SREBPs remains unclear and 
might not be appropriate for clinical applications. 




















































































Fig. 14 Chemical structures of gingerol, 4, and capsaicin. 
expression is efavirenz (Fig. 13), a non-nucleoside reverse 
transcriptase inhibitor used clinically to treat HIV. Efavirenz 
decreases levels of both SREBP-1c mRNA and its nuclear form 5 
in 3T3-L1 cells, reducing triglyceride accumulation during 
adipogenesis.105 Such SREBP inhibition is not observed with all 
non-nucleoside reverse transcriptase inhibitors,106 and the 
mechanism of efavirenz remains unknown.  
 A synthetic derivative of gingerol (Fig. 14), a bioactive natural 10 
product in ginger, provides another intriguing example. Ginger is 
used in natural medicine to treat a number of diseases, including 
diabetes, and an aqueous extract of ginger exhibited 
hypolipidaemic activity in rats.107 An amide derivative of 
gingerol (4, Fig. 14) suppressed the expression of SREBP-1c in 15 
mouse liver, reducing the weight gain induced by high-fat 
diets.108 Similarly to capsaicin (Fig. 14), which has anti-obesity 
activity, gingerol is known to activate transient receptor potential 
vanilloid 1 (TRPV1).109,110 The effect of molecule 4 on TRPV1 is 
unknown, and the relationship between TRPV1 and SREBP-1c 20 
remains unclear. However, further investigation of one or more of 
these molecules that indirectly affect SREBP expression could 
lead to new approaches for treating metabolic diseases.  
Conclusions 
SREBP transcription factors have been widely investigated since 25 
their discovery twenty years ago. As master regulators of 
lipogenesis, SREBPs are likely to be key players in a broad range 
of signaling events. There is recent evidence that SREBPs play 
regulatory roles in a number of physiological processes, including 
cancer growth, ER stress, immune response, and autophagy.14,21,22 30 
However, despite increasing knowledge of their physiological 
roles in lipogenesis and their molecular interactions, the exact 
regulatory mechanisms of SREBPs in vivo remain unclear and 
merit further investigation. Small molecules that control SREBPs 
would serve as useful tools to better understand the various roles 35 
of SREBPs, and to develop new pharmacological interventions 
for metabolic disorders and cancers. 
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